China-based Biokin has announced plans to issue debt financing instruments totalling up to RMB 10 billion (USD 1.4 billion) to support its R&D initiatives and optimise its capital structure. The proposed issuance may include medium-term notes, short-term financing bills and other instruments, with funds earmarked for R&D, debt repayment and potential strategic investments. This move follows a recent RMB 3.9 billion (USD 557 million) private placement approved in July 2025 and a strategic credit facility of at least RMB 8 billion (USD 1.1 billion) secured in November, highlighting the company's aggressive funding strategy to support its pipeline and global ambitions.

The company's lead asset, the EGFR/HER3 ADC izalontamab brengitecan, continues to advance, having recently secured a second priority review designation in China for oesophageal squamous cell carcinoma. Positive Phase III data for the drug in nasopharyngeal carcinoma were presented this year. A milestone payment of USD 250 million from Bristol Myers Squibb (BMS), tied to the global development of izalontamab brengitecan, has also been received. Biokin's deep pipeline includes other promising ADC candidates and multispecific antibodies, with R&D expenses on innovative drugs accounting for over 98% of its total R&D spend in H1 2025.

According to PharmCube's MedAlpha® database, Biokin has previously raised funds through a strategic investment, IPO, and post-IPO equity investment. Click here to request a free trial for MedAlpha®.